A large, newly published, observational study has suggested that comorbidity affects other-cause mortality but not prostate cancer-specific mortality after accounting for patient and tumor characteristics and treatment type. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: comorbidity, death, mortality, risk, Treatment | 3 Comments »
So we have all heard the commonly used phrase that men with diagnosed with prostate cancer are “more likely to die with prostate cancer than of it” — and there is certainly truth to this generalization. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: all-cause, comorbidity, mortality, recurrence, risk | Leave a comment »
Another newly published paper, this time in the British Journal of Urology, addresses issues related to cardiovascular disease and the treatment of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: comorbidity, localized, regret | 1 Comment »
There is good reason to believe that a very high percentage of older men — particularly those over 75 years with low-risk prostate cancer who have a life expectancy of 10 years or less — will get little to no clinical or survival benefit from active therapeutic intervention (although they should clearly be carefully monitored and given all appropriate care). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk, Treatment | Tagged: active, comorbidity, elderly. life expectancy, surveillance, Treatment | 2 Comments »
A clear appreciation of the associations between life expectancy, comorbid conditions (e.g., diabetes, obesity, cardiovascular disorders), and mortality is critically important to treatment decisions for all patients with prostate cancer, but most especially the newly diagnosed, low-risk patient. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: comorbidity, outcome, survival, Sweden, Treatment | Leave a comment »
A re-analysis of data from the prostate cancer screening arm of the Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening study has now stated that, “Selective use of PSA screening for men in good health appears to reduce the risk of [prostate cancer-specific mortality] with minimal overtreatment.” … READ MORE …
Filed under: Diagnosis, Risk | Tagged: comorbidity, healthy, PCLO, re-analysis, screening | 4 Comments »
Biochemical failure (also known as biochemical recurrence) after first-line treatment for prostate cancer is assessed based on a rising PSA level. This is a relatively common event and can happen shortly after first line treatment or many years later. The problem is that we really don’t know how important biochemical recurrence is in an individual patient at a specific point in time. After all, if a biochemical recurrence is never going to lead to clinical symptoms of prostate cancer (let alone prostate cancer-specific mortality), why would one want to treat it? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical recurrence, comorbidity, Management, risk, survival | Leave a comment »
D’Amico and his colleagues demonstrated some time ago that PSA velocity and PSA doubling time (PSADT) are valuable tools in predicting which patients with recurrent prostate cancer after first-line treatment are at greatest risk of metastatic disease and prostate cancer-specific mortality. But they have now shown that PSADT is less predictive of risk in men with other “comorbid” health problems. … READ MORE …
Filed under: Management, Treatment | Tagged: comorbidity, PSA doubling time, PSA velocity, PSADT, recurrence | Leave a comment »
Today’s news reports address:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: comorbidity, genitourinary toxicity, IMRT, race, risk, screening | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 